JP2017509624A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017509624A5 JP2017509624A5 JP2016556709A JP2016556709A JP2017509624A5 JP 2017509624 A5 JP2017509624 A5 JP 2017509624A5 JP 2016556709 A JP2016556709 A JP 2016556709A JP 2016556709 A JP2016556709 A JP 2016556709A JP 2017509624 A5 JP2017509624 A5 JP 2017509624A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- antibody
- patient
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 239000012634 fragment Substances 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 12
- 102000036639 antigens Human genes 0.000 claims 12
- 108091007433 antigens Proteins 0.000 claims 12
- 208000029078 coronary artery disease Diseases 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 108010028554 LDL Cholesterol Proteins 0.000 claims 6
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims 5
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims 5
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 4
- 206010000891 acute myocardial infarction Diseases 0.000 claims 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims 3
- 231100000682 maximum tolerated dose Toxicity 0.000 claims 3
- 206010002388 Angina unstable Diseases 0.000 claims 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims 2
- 108090001030 Lipoproteins Proteins 0.000 claims 2
- 102000004895 Lipoproteins Human genes 0.000 claims 2
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 2
- 208000007814 Unstable Angina Diseases 0.000 claims 2
- 230000000923 atherogenic effect Effects 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 230000000250 revascularization Effects 0.000 claims 2
- 101710095342 Apolipoprotein B Proteins 0.000 claims 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 claims 1
- 206010003178 Arterial thrombosis Diseases 0.000 claims 1
- 201000000057 Coronary Stenosis Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 208000033463 Ischaemic neuropathy Diseases 0.000 claims 1
- 229940122392 PCSK9 inhibitor Drugs 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000002583 angiography Methods 0.000 claims 1
- 230000007214 atherothrombosis Effects 0.000 claims 1
- 229940050446 atorvastatin 40 mg Drugs 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 230000002045 lasting effect Effects 0.000 claims 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 208000030613 peripheral artery disease Diseases 0.000 claims 1
- 230000000284 resting effect Effects 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000004904 shortening Methods 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461954094P | 2014-03-17 | 2014-03-17 | |
| US61/954,094 | 2014-03-17 | ||
| US201462025400P | 2014-07-16 | 2014-07-16 | |
| US62/025,400 | 2014-07-16 | ||
| US201462043182P | 2014-08-28 | 2014-08-28 | |
| US62/043,182 | 2014-08-28 | ||
| EP15305293 | 2015-02-26 | ||
| EP15305293.1 | 2015-02-26 | ||
| PCT/US2015/020564 WO2015142668A1 (en) | 2014-03-17 | 2015-03-13 | Methods for reducing cardiovascular risk |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020097344A Division JP2020143156A (ja) | 2014-03-17 | 2020-06-04 | 心血管リスクを低減させる方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017509624A JP2017509624A (ja) | 2017-04-06 |
| JP2017509624A5 true JP2017509624A5 (enExample) | 2018-04-12 |
Family
ID=52648962
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016556709A Pending JP2017509624A (ja) | 2014-03-17 | 2015-03-13 | 心血管リスクを低減させる方法 |
| JP2022116854A Pending JP2022141868A (ja) | 2014-03-17 | 2022-07-22 | 心血管リスクを低減させる方法 |
| JP2024115429A Pending JP2024147744A (ja) | 2014-03-17 | 2024-07-19 | 心血管リスクを低減させる方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022116854A Pending JP2022141868A (ja) | 2014-03-17 | 2022-07-22 | 心血管リスクを低減させる方法 |
| JP2024115429A Pending JP2024147744A (ja) | 2014-03-17 | 2024-07-19 | 心血管リスクを低減させる方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20150284473A1 (enExample) |
| EP (2) | EP4403213A3 (enExample) |
| JP (3) | JP2017509624A (enExample) |
| KR (3) | KR20160132459A (enExample) |
| CN (3) | CN114642661A (enExample) |
| AU (3) | AU2015231713B2 (enExample) |
| CA (1) | CA2942549A1 (enExample) |
| EA (1) | EA039310B1 (enExample) |
| ES (1) | ES2978990T3 (enExample) |
| HU (1) | HUE066839T2 (enExample) |
| IL (1) | IL304491A (enExample) |
| MX (1) | MX380767B (enExample) |
| PL (1) | PL3119810T3 (enExample) |
| WO (1) | WO2015142668A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| LT2443246T (lt) | 2009-06-15 | 2018-03-26 | Amarin Pharmaceuticals Ireland Limited | Kompozicijos ir būdai, skirti trigliceridų sumažinimui, nepakeliant ldl-c lygio subjekte, kartu taikant statino terapiją |
| SI2668212T1 (en) | 2011-01-28 | 2018-08-31 | Sanofi Biotechnology, | Human antibodies against PCSK9 for use in the treatment processes of certain groups of subjects |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| AU2012308797B2 (en) | 2011-09-16 | 2017-06-01 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PSCK9) |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| CN105705521A (zh) | 2013-06-07 | 2016-06-22 | 再生元制药公司 | 通过施用pcsk9抑制剂抑制动脉粥样硬化的方法 |
| US10428157B2 (en) | 2013-11-12 | 2019-10-01 | Sanofi Biotechnology | Dosing regimens for use with PCSK9 inhibitors |
| CA2954767A1 (en) * | 2014-07-14 | 2016-01-21 | Amgen Inc. | Crystalline antibody formulations |
| CN107206068A (zh) | 2014-07-16 | 2017-09-26 | 赛诺菲生物技术公司 | 用于治疗杂合型家族性高胆固醇血症(heFH)患者的方法 |
| PL3169362T3 (pl) * | 2014-07-16 | 2020-12-28 | Sanofi Biotechnology | Sposoby leczenia pacjentów wysokiego ryzyka sercowo-naczyniowego z hipercholesterolemią |
| US10472424B2 (en) | 2014-09-23 | 2019-11-12 | Pfizer Inc. | Treatment with anti-PCSK9 antibodies |
| KR20180034672A (ko) | 2015-08-18 | 2018-04-04 | 리제너론 파아마슈티컬스, 인크. | 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체 |
| JOP20190112A1 (ar) * | 2016-11-14 | 2019-05-14 | Amgen Inc | علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي |
| US10337070B2 (en) | 2017-01-12 | 2019-07-02 | Cardioforecast Ltd. | Methods and kits for treating cardiovascular disease |
| EP3609532A1 (en) | 2017-04-13 | 2020-02-19 | Cadila Healthcare Limited | Novel peptide based pcsk9 vaccine |
| JP7426940B2 (ja) * | 2018-03-06 | 2024-02-02 | サノフィ・バイオテクノロジー | 心血管リスクを低減するためのｐｃｓｋ９阻害剤の使用 |
| JP7513533B2 (ja) * | 2018-07-02 | 2024-07-09 | アブセントラ，エルエルシー | リポタンパク質ａの形成を減少させるための組成物及び方法、ならびに大動脈弁硬化症及び大動脈弁狭窄症の治療 |
| KR20210047312A (ko) * | 2018-08-17 | 2021-04-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 스타틴-치료 대상체에서 말초 동맥 혈관재개통에 대한 필요성을 감소시키는 방법 |
| JP7020756B2 (ja) | 2018-09-24 | 2022-02-16 | アマリン ファーマシューティカルズ アイルランド リミテッド | 対象の心血管イベントのリスクを低減する方法 |
| CA3125765A1 (en) | 2019-01-18 | 2020-07-23 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| EP4054625A1 (en) * | 2019-11-07 | 2022-09-14 | MedImmune, LLC | Endothelial lipase antibodies for the treatment of cardiovascular diseases |
| CN116350616A (zh) | 2019-11-12 | 2023-06-30 | 阿马里纳药物爱尔兰有限公司 | 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法 |
| IL323016A (en) * | 2019-11-18 | 2025-10-01 | Ad Pharmaceuticals Co Ltd | Anti-pcsk9 antibody and its use |
| WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| CN114848849B (zh) * | 2022-04-25 | 2023-11-17 | 南方科技大学 | Pcsk9蛋白抑制剂在治疗心血管疾病中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| SI2668212T1 (en) * | 2011-01-28 | 2018-08-31 | Sanofi Biotechnology, | Human antibodies against PCSK9 for use in the treatment processes of certain groups of subjects |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
-
2015
- 2015-03-13 PL PL15712241.7T patent/PL3119810T3/pl unknown
- 2015-03-13 JP JP2016556709A patent/JP2017509624A/ja active Pending
- 2015-03-13 CN CN202210141115.7A patent/CN114642661A/zh active Pending
- 2015-03-13 EA EA201691847A patent/EA039310B1/ru unknown
- 2015-03-13 US US14/657,192 patent/US20150284473A1/en not_active Abandoned
- 2015-03-13 WO PCT/US2015/020564 patent/WO2015142668A1/en not_active Ceased
- 2015-03-13 CN CN201580024259.2A patent/CN106794244A/zh active Pending
- 2015-03-13 MX MX2016011975A patent/MX380767B/es unknown
- 2015-03-13 CN CN202210141133.5A patent/CN114558129A/zh active Pending
- 2015-03-13 EP EP24160083.2A patent/EP4403213A3/en active Pending
- 2015-03-13 HU HUE15712241A patent/HUE066839T2/hu unknown
- 2015-03-13 KR KR1020167028383A patent/KR20160132459A/ko not_active Ceased
- 2015-03-13 EP EP15712241.7A patent/EP3119810B1/en active Active
- 2015-03-13 AU AU2015231713A patent/AU2015231713B2/en active Active
- 2015-03-13 KR KR1020247040556A patent/KR20250006995A/ko active Pending
- 2015-03-13 ES ES15712241T patent/ES2978990T3/es active Active
- 2015-03-13 KR KR1020227039740A patent/KR20220157516A/ko not_active Ceased
- 2015-03-13 CA CA2942549A patent/CA2942549A1/en active Pending
-
2021
- 2021-02-19 AU AU2021201118A patent/AU2021201118A1/en not_active Abandoned
- 2021-10-19 US US17/504,921 patent/US20220144969A1/en not_active Abandoned
-
2022
- 2022-07-22 JP JP2022116854A patent/JP2022141868A/ja active Pending
-
2023
- 2023-07-16 IL IL304491A patent/IL304491A/en unknown
-
2024
- 2024-07-19 JP JP2024115429A patent/JP2024147744A/ja active Pending
- 2024-07-31 AU AU2024205254A patent/AU2024205254A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017509624A5 (enExample) | ||
| Yu et al. | Expert consensus on the use of human serum albumin in critically ill patients | |
| JP2017506626A5 (enExample) | ||
| Soran et al. | Hypercholesterolaemia–practical information for non-specialists | |
| Teramoto et al. | Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins–ODYSSEY JAPAN Randomized Controlled Trial– | |
| Farnier et al. | Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY Phase 3 clinical program trials | |
| JP2017160208A5 (enExample) | ||
| JP2017503820A5 (enExample) | ||
| JP2017528427A5 (enExample) | ||
| JP2020002171A5 (enExample) | ||
| JP2016529255A5 (enExample) | ||
| Mercer et al. | Diabetes mellitus and the heart | |
| JP2012528796A5 (enExample) | ||
| Ito | Dyslipidemia: management using optimal lipid-lowering therapy | |
| JP2017522316A5 (enExample) | ||
| JP2014516953A5 (enExample) | ||
| FI2981255T3 (fi) | Empagliflotsiinin terapeuttiset käytöt | |
| JP2015164964A5 (enExample) | ||
| JP2016538277A5 (enExample) | ||
| CN107922507A (zh) | 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者 | |
| JP2016522196A5 (enExample) | ||
| JP2017535551A5 (enExample) | ||
| Coghlan et al. | Selexipag in the management of pulmonary arterial hypertension: an update | |
| Balafa et al. | Optimal medical management in patients with renovascular hypertension | |
| JP2020502134A5 (enExample) |